Press Releases for WPI

Press Releases
RidgewaterEquity.Com Free Fundamental Sector &Amp; Market Research on EXG, WPI, AVY, TTM, RBY and PHK
Warner Chilcott Files New Lawsuit for Infringement of LOESTRIN(R) 24 FE and FEMCON(R) FE Patents
Watson Prices $850 Million of Senior Unsecured Notes
Watson Announces Offering of Senior Unsecured Notes
Watson Announces Limited Recall Of Fentanyl Transdermal System
Watson Pharmaceuticals and Arrow Group Receive FTC Second Request
Stellar Pharmaceuticals Announces Record Second Quarter Revenues and Profitability for the First Half
Watson Pharmaceuticals Receives FDA Approval for Generic Toprol XL(R) 25 MG and 50 MG
Watson Pharmaceuticals Reports Second Quarter 2009 GAAP EPS of $0.46; Adjusted EPS $0.61; Company Raises 2009 Outlook
Recordati Signs an Agreement With Nycomed for the Co-Marketing of Silodosin in Italy
Watson Announces License Agreement With GeneraMedix for Generic Version of Ferrlecit(R)
Watson CFO Mark W. Durand to Take Leave of Absence
InvestorSoup.com Issues Trading Outlook for Labopharm Inc.
Watson Confirms Filing of Abbreviated New Drug Application for Generic Sanctura XR(R)
Watson Pharmaceuticals Receives a Complete Response Letter for Its 24-Week Formulation of TRELSTAR(R) (triptorelin pamoate) NDA from US FDA
Watson Pharmaceuticals Resumes Shipment of INFeD(R) (Iron Dextran Injection, USP)
Watson to Host Second Quarter 2009 Earnings Conference Call and Webcast
Watson Pharmaceuticals Receives FDA Approval for Fruit and Cinnamon Flavored Coated Nicotine Gums
Watson Pharmaceuticals Appoints Christopher W. Bodine to Board of Directors
Watson Pharmaceuticals Receives FDA Approval For Generic PLAN B(R)
Watson to Present at Wachovia's 19th Annual Mid-Year Equity Conference
InvestorSoup.com Issues In-Depth Look at: Watson, Edison Int'l, Scotts Miracle-Gro, Silicon Lab, Alvarion
Watson to Acquire Arrow Group
Watson Files FDA Application for Generic Mucinex(R) D
Watson to Present at Upcoming Investor Conferences
Depomed Names Shay Weisbrich Vice President of Marketing
Watson to Present at the UBS Global Specialty Pharmaceuticals Conference 2009
Watson to Present at the Sanford C. Bernstein & Co. Twenty-Fifth Annual Strategic Decisions 2009 Conference
Watson Launches GELNIQUE(TM) (oxybutynin chloride) Gel 10%, First and Only Topical Gel for Overactive Bladder (OAB)
Watson Provides Update on Ferrlecit(R) Supply and Distribution Agreement
Watson Promotes Patricia Eisenhaur to VP Investor Relations and Corporate Communications
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Watson to Present at Bank of America and Merrill Lynch 2009 Health Care Conference
Biovail Reports First-Quarter 2009 Financial Results
Watson Pharmaceuticals to Webcast Its 2009 Annual Meeting of Stockholders
Watson Pharmaceuticals Reports First Quarter 2009 Results; Raises 2009 Outlook
Presented Data Confirm That RAPAFLO(TM) (silodosin) Provides Rapid, Highly Effective, Symptom Relief for Benign Prostatic Hyperplasia (BPH) Patients
Watson Confirms Filing of Abbreviated New Drug Application for Generic Enablex(R)
New Data Presented at AUA's Annual Conference Prove GELNIQUE(TM) (oxybutynin chloride) 10% gel is an Effective, Safe Option for Female Overactive Bladder (OAB) Patients
Watson Files FDA Applications for Generic Mucinex(R)
Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting
Delaware Court Rules That Watson Does Not Infringe Patent Related to Generic Version of Concerta(R) and Declares Patent Invalid
Watson Announces a Nationwide Voluntary Recall of Propafenone HCL Tablets Due to Oversized Tablets
/C O R R E C T I O N -- Watson Pharmaceuticals, Inc./ - Mar 17 2009 3:29PM
Watson to Present at Cowen and Company 29th Annual Health Care Conference
Watson Pharmaceuticals and Elan Settle Lawsuit Over Naproxen Sodium
Recordati : 2008 Accounts Approved By the Board. Net Income + 18.3%. Dividend Per Share Eur 0.25
Watson to Present at Barclays Capital Global Healthcare Conference
Watson Pharmaceuticals Reports Fourth Quarter and Full Year 2008 Results; Provides 2009 Outlook
Watson to Host Fourth Quarter and Full Year 2008 Earnings Conference Call and Webcast
Watson's GELNIQUE(TM) (oxybutynin chloride) Gel 10% Approved by FDA for the Treatment of Overactive Bladder
Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
BenchmarkJournal.Com (Complimentary) Analyst Review for TGT, WPI, ALU and DFG
Watson to Present at the JP Morgan 27th Annual Healthcare Conference
Watson Pharmaceuticals Receives FDA Approval for Mint Coated Nicotine Gum
Watson Pharmaceuticals Receives FDA Final Approval for Generic Mircette(R)
Watson Pharmaceuticals Receives FDA Final Approval for Generic Wellbutrin XL(R) 150 mg
Watson Enters Into Agreement to Acquire Products Related to Teva's Proposed Acquisition of Barr
Watson Announces the NDA for a 6-Month Formulation of TRELSTAR(R) Accepted for Filing by FDA for the Treatment of Advanced Prostate Cancer
Watson to Present at the 2008 Annual Credit Suisse Health Care Conference
Watson Pharmaceuticals Reports Third Quarter 2008 Results
Watson Files Lawsuit Against Barr for OXYTROL Patent Infringement
Watson to Host Third Quarter 2008 Earnings Conference Call and Webcast
UPDATE: Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Watson Receives US FDA Approval for RAPAFLO(TM) (silodosin) for the Treatment of Benign Prostatic Hyperplasia (BPH)
Watson Announces Positive Data for Its Investigational Oxybutynin Topical Gel for the Treatment of Overactive Bladder at SUNA's Annual Conference
Watson Notified of OXYTROL(R) Patent Challenge
Watson Announces Positive Data for RAPAFLO(TM)(silodosin), Its Investigational Product for BPH, at Regional AUA Conferences
Watson Announces Change to Presentation Time at the Morgan Stanley Global Healthcare Unplugged Conference
Watson to Present at the Morgan Stanley Global Healthcare Unplugged Conference
Watson Announces District Court Ruling in Naproxen Sodium Patent Suit
Watson Pharmaceuticals Reports Second Quarter 2008 Results
Urologists Should Recognize the Cardiac Safety of Prescribed Medications, Article Concludes
Mylan Acquires Remaining Interest in Somerset Joint Venture From Watson
Watson Names Clare Carmichael Senior VP Human Resources
Watson Launches Omeprazole Delayed-Release Capsules, 40MG
Watson to Host Second Quarter 2008 Earnings Conference Call and Webcast
Watson Launches Generic MARINOL(R) Capsules
Watson to Present at the Goldman Sachs Twenty-Ninth Annual Global Healthcare Conference
Watson Receives FDA Approval of Potassium Chloride Extended-Release Capsules
Watson Receives Final Approval of Omeprazole Delayed-Release Capsules
Watson Announces Oxybutynin Topical Gel NDA Accepted for Filing by FDA for the Treatment of Overactive Bladder
Watson to Present at the UBS Global Specialty and Generic Pharmaceuticals Conference - May 26 2008 10:33PM
Watson Announces Positive Data for Its New Investigational Products for Benign Prostatic Hyperplasia and Overactive Bladder - May 27 2008 1:00AM
Watson to Host and Webcast Investment Community Meeting at American Urological Association Annual Meeting - Jun 2 2008 2:40AM
Watson Pharmaceuticals Announces Appointment of Andrew L. Turner as Chairman of the Board of Directors - Jun 2 2008 2:40AM
Watson to Present at the Bank of America 2008 Healthcare Conference - Jun 2 2008 2:40AM
Watson Pharmaceuticals to Webcast Its 2008 Annual Meeting of Stockholders - Jun 2 2008 2:40AM
Watson Pharmaceuticals Reports First Quarter 2008 Results - Jun 2 2008 2:39AM
FDA Approves MIXJECT(TM), a Convenient, Easy-to-Use Drug Delivery System For Watson Pharmaceutical's TRELSTAR(R) DEPOT and TRELSTAR(R) LA
Watson Announces Removal of FDA Official Action Indicated Status at Its Davie, Florida Facility
Watson Files FDA Application for Generic FENTORA(R)
Watson Files FDA Application for Generic YASMIN(R)
Watson to Host First Quarter 2008 Earnings Conference Call and Webcast